Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.

Abstract:

:Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in situ hybridization. Immunophenotyping analysis (CD20, CD3, CD10, Bcl-6, Mum-1) was also performed. MYC translocation was identified in 13 (12.3%) out of 106 cases. All MYC(+) DLBCLs showed a non-germinal center B-cell type. MYC(+) DLBCLs showed significantly poorer overall survival (OS) and progression-free survival, with a median OS and progression-free survival time of 4.7 and 3.2 months, respectively (p < 0.001). Multivariate analysis using a Cox proportional hazard model confirmed that MYC(+) (for OS, Hazards ratio 5.254; 95% CI, 2.354-11.723, p < 0.001) was the strongest independent predictor. DLBCL with MYC translocation is a subgroup of non-germinal center B-cell DLBCL with poor outcome. This may be a clinical characteristic that is specific to Chinese patients. Because only a few patients received rituximab, its usefulness could not be assessed. Future studies with larger numbers of patients are required.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Zhang HW,Chen ZW,Li SH,Bai W,Cheng NL,Wang JF

doi

10.1002/hon.991

subject

Has Abstract

pub_date

2011-12-01 00:00:00

pages

185-9

issue

4

eissn

0278-0232

issn

1099-1069

journal_volume

29

pub_type

杂志文章
  • R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.

    abstract::Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B-cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.829

    authors: Rueda A,Sabin P,Rifá J,Llanos M,Gómez-Codina J,Lobo F,García R,Herrero J,Provencio M,Jara C,Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL).

    更新日期:2008-03-01 00:00:00

  • Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.

    abstract::Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070605

    authors: Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

    更新日期:1989-11-01 00:00:00

  • Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9.

    abstract::The expression of two membrane antigens identified by the monoclonal antibodies (McAb) My9 and 3C5 has been investigated in cells from 80 acute leukemias. My9 was positive in the blasts of 33 out of the 38 (87 per cent) cases of acute myeloid leukemia (AML) tested, regardless of FAB subtype, and in 13 of 18 (72 per ce...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030306

    authors: Matutes E,Rodriguez B,Polli N,Tavares de Castro J,Parreira A,Andrews C,Griffin JD,Tindle RW,Catovsky D

    更新日期:1985-07-01 00:00:00

  • Primary bone marrow lymphoma is a rare neoplasm with poor outcome: case series from single tertiary care centre and review of literature.

    abstract::Primary bone marrow lymphoma is a rare disease and remains undiagnosed due to deceptive clinical presentation. Here, we report four cases of primary bone marrow B-cell non-Hodgkin lymphoma, which presented with cytopenias without any lymphadenopathy or organomegaly. Bone marrow examination revealed large atypical B-ce...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2178

    authors: Bhagat P,Sachdeva MU,Sharma P,Naseem S,Ahluwalia J,Das R,Varma N,Law A,Malhotra P

    更新日期:2016-03-01 00:00:00

  • Evidence of colony suppressor activity and deficiency of hematopoietic growth factors in hairy cell leukemia.

    abstract::The cause of myelosuppression in hairy cell leukemia (HCL) has been ascribed to a reduction of the circulating progenitor cell (CPC) compartment and to suppression of hematopoiesis by TNF-alpha. The present study was performed to evaluate the inhibitory effect of hairy cells (HCs) and a possible lack of hematopoietic ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900110207

    authors: Gasché C,Reinisch W,Schwarzmeier JD

    更新日期:1993-03-01 00:00:00

  • Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level.

    abstract::Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900120104

    authors: Parker D,Alison DL,Barnard DL,Child JA,Dovey G,Farish J,Norfolk DR,O'Brien CJ,Parapia LA,Sharp J

    更新日期:1994-01-01 00:00:00

  • Salvage chemotherapy for relapsed and resistant lymphoma with a carboplatin containing schedule--EPIC.

    abstract::We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900120304

    authors: Richardson DS,Tighe M,Cull G,Johnson SA,Phillips MJ

    更新日期:1994-05-01 00:00:00

  • Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study.

    abstract::This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 month...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.860

    authors: Neumann F,Markett J,Fenk R,Pooten M,Koch A,Bruennert D,Schimkus N,Wulfert M,Royer-Pokora B,Kronenwett R,Haas R,Gattermann N

    更新日期:2008-12-01 00:00:00

  • Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.

    abstract::Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2775

    authors: Viviani S,Mazzocchi A,Pavoni C,Taverna F,Rossi A,Patti C,Romano A,Trentin L,Sorasio R,Guidetti A,Gottardi D,Tarella C,Cimminiello M,Zanotti R,Farina L,Ferreri AJM,Galbiati M,Corradini P,Gianni AM,Gallamini A,Ramba

    更新日期:2020-10-01 00:00:00

  • The value of EUS in combination with cytological, flow cytometry, and gene rearrangement in the diagnosis of gastrointestinal lymphoma.

    abstract::Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2298

    authors: Yu L,Chen K,Xu Y,Wang S,Liu Q,Ye Q,Ye T,Sun Y

    更新日期:2017-09-01 00:00:00

  • COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma.

    abstract::One hundred and forty-one consecutive patients above and 231 below the age of 60 years with previously untreated intermediate or high grade non-Hodgkin's lymphoma were included in this study. Patients above the age of 60 years were treated with the COPP chemotherapy regimen. The younger patients, at or below the age o...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2900110106

    authors: Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho F

    更新日期:1993-01-01 00:00:00

  • Increasing incidence of non-Hodgkin's lymphoma in Canada, 1970-1996: age-period-cohort analysis.

    abstract::Previous studies have shown that the incidence of non-Hodgkin's lymphoma (NHL) has increased in many parts of the world in recent decades. Using data obtained from the Canadian Cancer Registry, the present study examined time trends in NHL incidence in Canada between 1970 and 1996 and the effects of age, period of dia...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.703

    authors: Liu S,Semenciw R,Mao Y

    更新日期:2003-06-01 00:00:00

  • The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA.

    abstract::This report summarizes a closed workshop cosponsored by the American Association for Cancer Research, the European School of Oncology, and the 15th-International Conference on Malignant Lymphoma to discuss critical open questions on liquid biopsy in lymphoid malignancies, develops a roadmap for their analytical and cl...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2704

    authors: Rossi D,Kurtz DM,Roschewski M,Cavalli F,Zucca E,Wilson WH

    更新日期:2020-02-01 00:00:00

  • ABCG2 (BCRP) expression in normal and malignant hematopoietic cells.

    abstract::ABCG2 (BCRP) is a member of the ATP-binding cassette (ABC) family of cell surface transport proteins. ABCG2 expression occurs in a variety of normal tissues, and is relatively limited to primitive stem cells. ABCG2 expression is associated with the side population (SP) phenotype of Hoechst 33342 efflux. The substrate ...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.714

    authors: Abbott BL

    更新日期:2003-09-01 00:00:00

  • Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology.

    abstract::B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD patho...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.859

    authors: Vakiani E,Basso K,Klein U,Mansukhani MM,Narayan G,Smith PM,Murty VV,Dalla-Favera R,Pasqualucci L,Bhagat G

    更新日期:2008-12-01 00:00:00

  • Glucose-6-phosphatase activity of Reed-Sternberg and Hodgkin cells.

    abstract::The glucose-6-phosphatase (G-6-Pase) enzyme cytochemical reaction was successfully applied on lymph node imprints, after introducing the appropriate modifications related to fixation and to composition of the substrate solutions. Using this method we studied the G-6-Pase cytochemical profile on lymph node imprint prep...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900040403

    authors: Pangalis GA,Tsavaris NB

    更新日期:1986-10-01 00:00:00

  • Inducible lymphokine-activated killer (LAK) cell activity in the peripheral blood of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL).

    abstract::Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080205

    authors: Zamkoff KW,Watman NP,Duggan DB,Poiesz BJ,Gottlieb AJ

    更新日期:1990-03-01 00:00:00

  • The new World Health Organization classification of lymphomas: the past, the present and the future.

    abstract::The REAL Classification of lymphomas, proposed in 1994, represents a new paradigm in lymphoma classification, consisting of a list of biologic entities defined by clinicopathologic and immunogenetic features. The non-Hodgkin's lymphomas comprise precursor lymphoblastic and mature cell neoplasms of B, T or putative nat...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.660

    authors: Chan JK

    更新日期:2001-12-01 00:00:00

  • Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders.

    abstract::Post-transplant lymphoproliferative disorders (PTLD) derive from antigen-experienced B-cells and represent a major complication of solid organ transplantation. We characterized usage, mutation frequency and mutation pattern of immunoglobulin variable (IGV) gene rearrangements in 50 PTLD (polymorphic PTLD, n=10; diffus...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.791

    authors: Capello D,Cerri M,Muti G,Lucioni M,Oreste P,Gloghini A,Berra E,Deambrogi C,Franceschetti S,Rossi D,Alabiso O,Morra E,Rambaldi A,Carbone A,Paulli M,Gaidano G

    更新日期:2006-12-01 00:00:00

  • No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.

    abstract::This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough ) and intracellular (IMA Cintrac ) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7-4628.1 ng/ml). We found a correlation between...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2091

    authors: Racil Z,Razga F,Klamova H,Voglova J,Belohlavkova P,Malaskova L,Potesil D,Muzik J,Zackova D,Polakova KM,Zdrahal Z,Malakova J,Suttnar J,Dyr J,Mayer J

    更新日期:2014-06-01 00:00:00

  • Aberrant immunoarchitecture distinguishes hyperplastic germinal centres in pattern 1 angioimmunoblastic T-cell lymphoma from reactive follicles.

    abstract::We compare 30 biopsies each of Pattern 1 angioimmunoblastic T-cell lymphoma (AITL1) and reactive lymphoid hyperplasia (RLH) by immunohistology, in-situ hybridization for Epstein-Barr virus-encoded RNA and T-cell receptor-γ (TRG)-clonality. AITL1 cases, more often than RLH controls, were older [median ages 61 (range 23...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2116

    authors: Tan LH,Tan SY

    更新日期:2014-09-01 00:00:00

  • Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.

    abstract::Bone marrow (BM) trephine biopsy is a part of routine staging of patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). The significance of lymphoid monoclonal population on flow cytometry (FC) of the BM aspirate in the presence of negative BM histology has not been clarified. In this study, we assessed ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2127

    authors: Wolach O,Fraser A,Luchiansky M,Shapiro C,Radnay J,Shpilberg O,Lishner M,Lahav M

    更新日期:2015-03-01 00:00:00

  • Large cell lymphoma with initial presentation in the bone marrow.

    abstract::This report describes 14 cases of large cell lymphoma with initial presentation as marrow involvement in the absence of peripheral lymphadenopathy. The disease affected mainly the middle-aged and elderly, with male predominance. Most patients presented with swinging fever and peripheral blood cytopenia. Reactive hemop...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100504

    authors: Wong KF,Chan JK,Ng CS,Chu YC,Li LP,Chan CH

    更新日期:1992-09-01 00:00:00

  • Chemical and thyroid hormone profile of the bone marrow interstitial fluid in hematologic disorders and patients without primary hematologic disorders.

    abstract::Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constit...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2493

    authors: Krashin E,Ellis M,Cohen K,Viner M,Neumark E,Rashid G,Ashur-Fabian O

    更新日期:2018-04-01 00:00:00

  • Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.

    abstract::There is a high incidence of genomic aberration of ataxia telangiectasia mutated (ATM) and genes encoding proteins involved in the ATM pathway in mantle cell lymphoma (MCL). It has been shown that poly(ADP-ribose) polymerase inhibitor (PARPi) strongly enhances the cytotoxicity of agents, causing single-strand DNA brea...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.1020

    authors: Golla RM,Li M,Shen Y,Ji M,Yan Y,Fu K,Greiner TC,McKeithan TW,Chan WC

    更新日期:2012-12-01 00:00:00

  • Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma.

    abstract::Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overa...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2522

    authors: Thompson CA,Yost KJ,Maurer MJ,Allmer C,Farooq U,Habermann TM,Inwards DJ,Macon WR,Link BK,Rosenthal AC,Cerhan JR

    更新日期:2018-12-01 00:00:00

  • Establishment of a novel human B-cell line (OZ) with t(14;18)(q32;q21) and aberrant p53 expression was associated with the homozygous deletions of p15INK4B and p16INK4A genes.

    abstract::The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alterations on chromoso...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199708)15:3<109::aid-hon60

    authors: Nagai M,Fujita M,Ohmori M,Matsubara S,Taniwaki M,Horiike S,Tasaka T,Koeffler HP,Takahara J

    更新日期:1997-08-01 00:00:00

  • Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.

    abstract::Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.1017

    authors: Gu K,Weisenburger DD,Fu K,Chan WC,Greiner TC,Aoun P,Smith LM,Bast M,Liu Z,Bociek RG,Bierman PJ,Armitage JO,Vose JM

    更新日期:2012-09-01 00:00:00

  • Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.

    abstract::Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2532

    authors: Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

    更新日期:2018-10-01 00:00:00

  • Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.

    abstract::Langerhans cell histiocytosis (LCH) is rare in adults, and only a subset of these patients suffers from central nervous system (CNS) involvement. Hence, evidence-based treatment recommendations are lacking. A case of a 20-year-old student with multisystem LCH and extensive CNS involvement is described, who showed a du...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.1005

    authors: Baumann M,Cerny T,Sommacal A,Koeberle D

    更新日期:2012-06-01 00:00:00